BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
BC Extra | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

Four biotechs set terms for U.S. IPOs Monday in a month that has already seen five go public, including the largest raise of the year. Collectively, the quartet could raise over $500 million. ADC Therapeutics...
BC Extra | Sep 18, 2019
Financial News

Sept. 18 Financial Quick Takes: IGM gains in first trading day; plus a follow-on roundup, BenevolentAI, UCSF’s InVent Fund and Versantis

First-day pop for IGM on NASDAQ  Oncology antibody company IGM Biosciences Inc. (NASDAQ:IGMS) gained $8.30 (52%) to $24.30 in its first day of trading after raising $175 million in its IPO. IGM sold 10.9 million...
BC Extra | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

BrightGene advances toward STAR market   The Shanghai Stock Exchange approved an application from BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) to raise RMB360 million ($50.3 million) in a listing on its STAR market. If...
BC Extra | Aug 20, 2019
Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

Juvenescence closes $100M series B  Juvenescence Ltd. (Douglas, Isle of Man) said it has closed its $100 million series B round and reiterated plans to seek an IPO. Investors included the company's founders plus Grok...
BC Extra | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings  Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also...
BC Extra | Jul 9, 2019
Financial News

July 8 Financial Quick Takes: IGM raises mega-round; plus Mirium, Fulcrum set IPO ranges and more

IGM raises $102M C round IGM Biosciences Inc. (Mountain View, Calif.) raised $102 million in a series C round that included new investors Redmile Group, Janus Henderson Investors, Vivo Capital and an undisclosed U.S.-based healthcare...
BC Extra | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
BC Innovations | Feb 26, 2019
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for making iPS cells hypoimmunogenic could be used to generate allogeneic cell grafts for transplant therapies. The method involves two to three steps: simultaneous or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated...
Items per page:
1 - 10 of 152